Citations (176)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Xiaotong Chen, Yanqiu Zhao, Qi Li & Shengjin Fan. (2023) Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML. OncoTargets and Therapy 16, pages 409-419.
Read now
Read now
Yu Lian, Juanjuan Ti, Liangming Ma, Jia Wei & Zhilin Gao. (2023) Analysis and clinical characteristics of acute myeloid leukemia developing with prior or concurrent tumors in non cyto- or radiotherapy exposure patients in a single center. Hematology 28:1.
Read now
Read now
Tabea Sutter, Marcus Schittenhelm, Thomas Volken & Thomas Lehmann. (2023) Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis. Hematology 28:1.
Read now
Read now
Xiaoya Shao, Xueqiong Meng, Haiping Yang, Xinxin Wang, Ling Qin, Guomin Shen, Xiaoping Xi, Huijuan Zhao, Salvador Macip & Yixiang Chen. (2023) IFN-γ enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway. Leukemia & Lymphoma 64:1, pages 71-78.
Read now
Read now
Matteo Molica & Salvatore Perrone. (2022) Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours. Expert Review of Hematology 15:11, pages 973-986.
Read now
Read now
Pratik Pal, Peiyi Zhang, Saikat K. Poddar & Guangrong Zheng. (2022) Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins. Expert Opinion on Therapeutic Patents 32:9, pages 1003-1026.
Read now
Read now
Omar Raslan & Alejandro Garcia-Horton. (2022) Azacitidine and its role in the upfront treatment of acute myeloid leukemia. Expert Opinion on Pharmacotherapy 23:8, pages 873-884.
Read now
Read now
Sonal Agarwal, Andrew Kowalski, Molly Schiffer, Jennifer Zhao, Jan Philipp Bewersdorf & Amer M. Zeidan. (2021) Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?. Expert Review of Hematology 14:2, pages 199-210.
Read now
Read now
Maria I. Edilova, Jaclyn C. Law, Safoura Zangiabadi, Kenneth Ting, Achire N. Mbanwi, Andrea Arruda, David Uehling, Methvin Isaac, Michael Prakesch, Rima Al-awar, Mark D. Minden, Ali A. Abdul-Sater & Tania H. Watts. (2021) The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia. OncoImmunology 10:1.
Read now
Read now
Somedeb Ball & Gautam Borthakur. (2020) Apoptosis targeted therapies in acute myeloid leukemia: an update. Expert Review of Hematology 13:12, pages 1373-1386.
Read now
Read now
Dong Won Baek, Juhyung Kim, Hee Jeong Cho, Joon Ho Moon & Sang Kyun Sohn. (2020) Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation. Expert Review of Hematology 13:9, pages 959-969.
Read now
Read now
Curtis Lachowiez, Courtney D. DiNardo & Marina Konopleva. (2020) Venetoclax in acute myeloid leukemia – current and future directions . Leukemia & Lymphoma 61:6, pages 1313-1322.
Read now
Read now
Mansour Alfayez, Beenu Thakral, Preetesh Jain, Farhad Ravandi, Alessandra Ferrajoli, Nitin Jain, Naveen Pemmaraju, William Wierda & Tapan Kadia. (2020) First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leukemia & Lymphoma 61:2, pages 445-449.
Read now
Read now
Anna Korycka-Wolowiec, Dariusz Wolowiec, Aleksandra Kubiak-Mlonka & Tadeusz Robak. (2019) Venetoclax in the treatment of chronic lymphocytic leukemia. Expert Opinion on Drug Metabolism & Toxicology 15:5, pages 353-366.
Read now
Read now
Ji-Xia Ren, Cheng-Ping Li, Xiu-Ling Zhou, Xue-Song Cao & Yong Xie. (2018) In silico approaches to identify novel myeloid cell leukemia-1 (Mcl-1) inhibitors for treatment of cancer. Journal of Biomolecular Structure and Dynamics 36:9, pages 2424-2435.
Read now
Read now
Steven Grant. (2018) Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies. Leukemia & Lymphoma 59:6, pages 1292-1299.
Read now
Read now
Abdallah Abou Zahr, Prithviraj Bose & Michael J. Keating. (2017) Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 18:9, pages 857-873.
Read now
Read now
Articles from other publishers (159)
Anupriya Bandyopadhyay, Tuyelee Das, Samapika Nandy, Synudeen Sahib, Subham Preetam, Abilash Valsala Gopalakrishnan & Abhijit Dey. (2023) Ligand-based active targeting strategies for cancer theranostics. Naunyn-Schmiedeberg's Archives of Pharmacology 396:12, pages 3417-3441.
Crossref
Crossref
Amanda Reyes & Tanya Siddiqi. (2023) Targeting BCL2 pathways in CLL: a story of resistance and ingenuity. Cancer Drug Resistance 6:4, pages 828-37.
Crossref
Crossref
Maria Leśniak, Justyna Lipniarska, Patrycja Majka, Monika Lejman & Joanna Zawitkowska. (2023) Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies. International Journal of Molecular Sciences 24:23, pages 16708.
Crossref
Crossref
Seth E. Karol & Gwenaelle Gueguen. (2023) Pediatric acute myeloid leukemia – novel approaches. Current Opinion in Hematology.
Crossref
Crossref
Wojciech Wiese, Julia Barczuk, Olga Racinska, Natalia Siwecka, Wioletta Rozpedek-Kaminska, Artur Slupianek, Radoslaw Sierpinski & Ireneusz Majsterek. (2023) PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities. Cancers 15:21, pages 5297.
Crossref
Crossref
Gelina S. Kopeina & Boris Zhivotovsky. (2023) The New Face of Autophagy in Chronic Lymphocytic Leukemia. Cancers 15:21, pages 5279.
Crossref
Crossref
Yijing Li, Heng-Huan Lee, Vivian Changying Jiang, Yuxuan Che, Joseph McIntosh, Alexa Jordan, Jovanny Vargas, Tianci Zhang, Fangfang Yan, Margaret Elizabeth Simmons, Wei Wang, Lei Nie, Yixin Yao, Preetesh Jain, Michael Wang & Yang Liu. (2023) Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins. Cell Death & Disease 14:11.
Crossref
Crossref
Enrico Santinelli, Maria Rosaria Pascale, Zhuoer Xie, Talha Badar, Maximilian F. Stahl, Jan P. Bewersdorf, Carmelo Gurnari & Amer M. Zeidan. (2023) Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution. Blood Reviews 62, pages 101130.
Crossref
Crossref
Zhifeng Li, Guangchao Pan, Mengya Zhong, Li Zhang, Xingxing Yu, Jie Zha & Bing Xu. (2023) High-Throughput Drug Screen for Potential Combinations With Venetoclax Guides the Treatment of Transformed Follicular Lymphoma. International Journal of Toxicology 42:5, pages 386-406.
Crossref
Crossref
Alexus Acton & William J. Placzek. (2023) Myeloid Cell Leukemia 1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Triple-Negative Breast Cancer. Cancers 15:18, pages 4481.
Crossref
Crossref
Flore Sneyers, Martijn Kerkhofs, Femke Speelman-Rooms, Kirsten Welkenhuyzen, Rita La Rovere, Ahmed Shemy, Arnout Voet, Guy Eelen, Mieke Dewerchin, Stephen W. G. Tait, Bart Ghesquière, Martin D. Bootman & Geert Bultynck. (2023) Intracellular BAPTA directly inhibits PFKFB3, thereby impeding mTORC1-driven Mcl-1 translation and killing MCL-1-addicted cancer cells. Cell Death & Disease 14:9.
Crossref
Crossref
Fanghua Ye, Wen Zhang, Chenying Fan, Jiajia Dong, Min Peng, Wenjun Deng, Hui Zhang & Liangchun Yang. (2023) Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis. Journal of Translational Medicine 21:1.
Crossref
Crossref
Megan Jung, Indy Bui & Benjamin Bonavida. (2023) Role of YY1 in the Regulation of Anti-Apoptotic Gene Products in Drug-Resistant Cancer Cells. Cancers 15:17, pages 4267.
Crossref
Crossref
Rui Caetano Oliveira, João Gama & José Casanova. (2023) B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease. Exploration of Targeted Anti-tumor Therapy, pages 583-599.
Crossref
Crossref
Nicholas J. Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D. Dinardo, Gautam Borthakur, Nitin Jain, Maro Ohanian, Elias Jabbour, Ghayas C. Issa, Wei Qiao, Xuelin Huang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Prithviraj Bose, Farhad Ravandi, Ricardo Delumpa, Regina Abramova, Guillermo Garcia-Manero, Michael Andreeff, Jorge Cortes & Hagop Kantarjian. (2023) A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. Journal of Hematology & Oncology 16:1.
Crossref
Crossref
Yasuhiro Kano, Haruka Okada & Kengo Murata. (2023) Hot lung sign in intravascular lymphoma. BMJ Case Reports 16:7, pages e256987.
Crossref
Crossref
Jiasheng Wang, Benjamin Tomlinson & Hillard M. Lazarus. (2023) Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia. Current Treatment Options in Oncology 24:7, pages 770-801.
Crossref
Crossref
Lisa Haasler, Claudia von Montfort, Arun Kumar Kondadi, Mathias Golombek, Lara Ebbert, Chantal-Kristin Wenzel, Wilhelm Stahl, Andreas S. Reichert & Peter Brenneisen. (2023) Involvement of necroptosis in the selective toxicity of the natural compound (±) gossypol on squamous skin cancer cells in vitro. Archives of Toxicology 97:7, pages 1997-2014.
Crossref
Crossref
Marlen Michalski, Magdalena Bauer, Franziska Walz, Deniz Tümen, Philipp Heumann, Petra Stöckert, Manuela Gunckel, Claudia Kunst, Arne Kandulski, Stephan Schmid, Martina Müller & Karsten Gülow. (2023) Simultaneous Inhibition of Mcl-1 and Bcl-2 Induces Synergistic Cell Death in Hepatocellular Carcinoma. Biomedicines 11:6, pages 1666.
Crossref
Crossref
Yihan Zhao, Shiqing Jiang, Yujun Tang & Lin Zhao. (2023) Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review. International Journal of Hematology.
Crossref
Crossref
Dilip Panwar, Pradip Thakor, Madhu Sharma, Avijit Kumar Bakshi, Valamla Bhavana, Vaibhavi Srivastava, Prabhat Ranjan Mishra, Shashi Bala Singh & Neelesh Kumar Mehra. (2023) Hyaluronic acid-engineered Bcl-2 inhibitor nanocrystals for site-specific delivery to breast tumor cells. Nanomedicine 18:15, pages 1005-1023.
Crossref
Crossref
Zi‐Ning Lei, Qin Tian, Qiu‐Xu Teng, John N. D. Wurpel, Leli Zeng, Yihang Pan & Zhe‐Sheng Chen. (2023) Understanding and targeting resistance mechanisms in cancer. MedComm 4:3.
Crossref
Crossref
Salvatore Perrone, Paolo Lopedote, Vitaliana De Sanctis, Ilenia Iamundo De Cumis, Alessandro Pulsoni & Paolo Strati. (2023) Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond. Cancers 15:10, pages 2751.
Crossref
Crossref
Matteo Piccini, Francesco Mannelli & Giacomo Coltro. (2023) The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions. Bioengineering 10:5, pages 591.
Crossref
Crossref
Zsuzsanna Valko, Zsolt Megyesfalvi, Anna Schwendenwein, Christian Lang, Sandor Paku, Nandor Barany, Bence Ferencz, Anita Horvath-Rozsas, Ildiko Kovacs, Erzsebet Schlegl, Veronika Pozonec, Kristiina Boettiger, Melinda Rezeli, Gyorgy Marko-Varga, Ferenc Renyi-Vamos, Mir Alireza Hoda, Thomas Klikovits, Konrad Hoetzenecker, Michael Grusch, Viktoria Laszlo, Balazs Dome & Karin Schelch. (2023) Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer. British Journal of Cancer 128:10, pages 1850-1861.
Crossref
Crossref
Ian M. Bouligny, Graeme Murray, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Nolan A. Wages, Steven Grant & Keri R. Maher. (2023) Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia. eJHaem 4:2, pages 381-392.
Crossref
Crossref
Mihaela Andreescu, Nicoleta Berbec & Alina Tanase. (2023) Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia. Journal of Clinical Medicine 12:7, pages 2731.
Crossref
Crossref
Liberalis Debraj Boila, Subhadeep Ghosh, Subham K. Bandyopadhyay, Liqing Jin, Alex Murison, Andy G. X. Zeng, Wasim Shaikh, Satyaki Bhowmik, Siva Sai Naga Anurag Muddineni, Mayukh Biswas, Sayantani Sinha, Shankha Subhra Chatterjee, Nathan Mbong, Olga I. Gan, Anwesha Bose, Sayan Chakraborty, Andrea Arruda, James A. Kennedy, Amanda Mitchell, Eric R. Lechman, Debasis Banerjee, Michael Milyavsky, Mark D. Minden, John E. Dick & Amitava Sengupta. (2023) KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition. Leukemia 37:4, pages 751-764.
Crossref
Crossref
Bita Fakhri & Alexey Danilov. (2023) SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 23:4, pages 232-237.
Crossref
Crossref
Soumi Mukherjee, Gurjit Kaur Bhatti, Ravindresh Chhabra, P. Hemachandra Reddy & Jasvinder Singh Bhatti. (2023) Targeting mitochondria as a potential therapeutic strategy against chemoresistance in cancer. Biomedicine & Pharmacotherapy 160, pages 114398.
Crossref
Crossref
Kelsey H. Fisher-Wellman, Miki Kassai, James T. Hagen, P. Darrell Neufer, Mark Kester, Thomas P. LoughranJr.Jr., Charles E. Chalfant, David J. Feith, Su-Fern Tan, Todd E. Fox, Johnson Ung, Gemma Fabrias, Jose’ Luis Abad, Arati Sharma, Upendarrao Golla, David F. Claxton, Jeremy J. P. Shaw, Debajit Bhowmick & Myles C. Cabot. (2023) Simultaneous Inhibition of Ceramide Hydrolysis and Glycosylation Synergizes to Corrupt Mitochondrial Respiration and Signal Caspase Driven Cell Death in Drug-Resistant Acute Myeloid Leukemia. Cancers 15:6, pages 1883.
Crossref
Crossref
Ana Portelinha, Mariana da Silva Ferreira, Tatiana Erazo, Man Jiang, Zahra Asgari, Elisa de Stanchina, Anas Younes & Hans-Guido Wendel. (2023) Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma. Nature Communications 14:1.
Crossref
Crossref
Pablo Galindo-Navarro, Alicia Delgado-García, Miguel A Rodríguez-Gil & José M Puerta-Puerta. (2023) Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain. Haematologica 108:8, pages 2261-2264.
Crossref
Crossref
Rong-Hua Hu, Li Su, Xiao-Xi Lan, Xiao-Li Chang, Wu-Han Hui, Yi-Xian Guo, Hong Zhao, Yue Zhang & Wan-Ling Sun. (2022) A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia. Anti-Cancer Drugs 34:3, pages 344-350.
Crossref
Crossref
Yang Wang & Randy Y. C. Poon. (2022) MARCH5 regulates mitotic apoptosis through MCL1-dependent and independent mechanisms. Cell Death & Differentiation 30:3, pages 753-765.
Crossref
Crossref
Rabea Mecklenbrauck & Michael Heuser. (2022) Resistance to targeted therapies in acute myeloid leukemia. Clinical & Experimental Metastasis 40:1, pages 33-44.
Crossref
Crossref
Lijia Chen, Jay Chauhan, Jeremy L. Yap, Christopher C. Goodis, Paul T. Wilder & Steven Fletcher. (2023)
Discovery of
N
-sulfonylated aminosalicylic acids as dual MCL-1/BCL-xL inhibitors
. RSC Medicinal Chemistry 14:1, pages 103-112.
Crossref
Crossref
Qian Chen, Lindon Young & Robert Barsotti. 2023.
35
91
.
Wolfgang A. SchulzWolfgang A. Schulz. 2023. Molecular Biology of Human Cancers. Molecular Biology of Human Cancers
483
534
.
Yang Yang, Yamin Shu, Guosong Chen, Yanchao Yin, Feie Li & Juan Li. (2022) A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax. PLOS ONE 17:12, pages e0278725.
Crossref
Crossref
Yilan Xu & Haige Ye. (2022) Progress in understanding the mechanisms of resistance to BCL-2 inhibitors. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Liqin Cao, Qingxiao Chen, Huiyao Gu, Yi Li, Wen Cao, Yang Liu, Jianwei Qu, Yifan Hou, Jing Chen, Enfan Zhang, Jingsong He & Zhen Cai. (2022) Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression. Clinical Epigenetics 14:1.
Crossref
Crossref
Paula Hoffmeister‐Wittmann, Andreas Mock, Federico Nichetti, Felix Korell, Christoph E. Heilig, Anna‐Lena Scherr, Michael Günther, Thomas Albrecht, Eblina Kelmendi, Kaiyu Xu, Luisa Nader, Annika Kessler, Nathalie Schmitt, Sarah Fritzsche, Sofia Weiler, Benjamin Sobol, Albrecht Stenzinger, Stefan Boeck, Christoph B. Westphalen, Klaus Schulze‐Osthoff, Jörg Trojan, Thomas Kindler, Wilko Weichert, Karsten Spiekermann, Michael Bitzer, Gunnar Folprecht, Anna L. Illert, Melanie Boerries, Frederick Klauschen, Sebastian Ochsenreither, Jens Siveke, Sebastian Bauer, Hanno Glimm, Benedikt Brors, Jennifer Hüllein, Daniel Hübschmann, Sebastian Uhrig, Peter Horak, Simon Kreutzfeldt, Jesus M. Banales, Christoph Springfeld, Dirk Jäger, Peter Schirmacher, Stephanie Roessler, Steffen Ormanns, Benjamin Goeppert, Stefan Fröhling & Bruno C. Köhler. (2022)
Bcl‐x
L
as prognostic marker and potential therapeutic target in cholangiocarcinoma
. Liver International 42:12, pages 2855-2870.
Crossref
Crossref
Shuang Liu, Xinan Qiao, Shuangshuang Wu, Yuqinq Gai, Yongwei Su, Holly Edwards, Yue Wang, Hai Lin, Jeffrey W. Taub, Guan Wang & Yubin Ge. (2022) c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia. Apoptosis 27:11-12, pages 913-928.
Crossref
Crossref
Lijia Chen, Alexandria M. Chan, Paul T. Wilder & Steven Fletcher. (2022) 1‐Sulfonylated 1,2,3,4‐tetrahydroquinoline‐6‐carboxylic acids as simple, readily‐accessible MCL‐1 inhibitors. Drug Development Research 83:8, pages 1879-1889.
Crossref
Crossref
D. Thomalla, L. Beckmann, C. Grimm, M. Oliverio, L. Meder, C. D. Herling, P. Nieper, T. Feldmann, O. Merkel, E. Lorsy, A. da Palma Guerreiro, J. von Jan, I. Kisis, E. Wasserburger, J. Claasen, E. Faitschuk-Meyer, J. Altmüller, P. Nürnberg, T.-P. Yang, M. Lienhard, R. Herwig, K.-A. Kreuzer, C. P. Pallasch, R. Büttner, S. C. Schäfer, J. Hartley, H. Abken, M. Peifer, H. Kashkar, G. Knittel, B. Eichhorst, R. T. Ullrich, M. Herling, H. C. Reinhardt, M. Hallek, M. R. Schweiger & L. P. Frenzel. (2022) Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood 140:20, pages 2113-2126.
Crossref
Crossref
Shivanthy Pathmanathan, Zhong Yao, Paula Coelho, Robert Valla, Luka Drecun, Caroline Benz, Jamie Snider, Punit Saraon, Ingrid Grozavu, Max Kotlyar, Igor Jurisica, Morag Park & Igor Stagljar. (2022) B cell linker protein (BLNK) is a regulator of Met receptor signaling and trafficking in non-small cell lung cancer. iScience 25:11, pages 105419.
Crossref
Crossref
Padakanti Sandeep Chary, Naveen Rajana, Geetanjali Devabattula, Valamla Bhavana, Hoshiyar Singh, Chandraiah Godugu, Santosh Kumar Guru, Shashi Bala Singh & Neelesh Kumar Mehra. (2022) Design, Fabrication and Evaluation of Stabilized Polymeric mixed micelles for Effective Management in Cancer Therapy. Pharmaceutical Research 39:11, pages 2761-2780.
Crossref
Crossref
Merve Kulbay, Adeline Paimboeuf, Derman Ozdemir & Jacques Bernier. (2021) Review of cancer cell resistance mechanisms to apoptosis and actual targeted therapies. Journal of Cellular Biochemistry 123:11, pages 1736-1761.
Crossref
Crossref
Nina Nguyen, Sana Chaudhry, Tulasigeri M. Totiger, Robert Diaz, Evan Roberts, Skye Montoya, Gabriel Pardo, Alejandro Pardo, Jumana Afaghani, Maurizio Affer, Jacob Jahn, Terrence Bradley, Francesco Maura, Dickran Kazandjian, Daniel Bilbao, Jennifer Chapman, Ola Landgren, James Hoffman & Justin Taylor. (2022) Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14). npj Precision Oncology 6:1.
Crossref
Crossref
Shanna Qian, Zhong Wei, Wanting Yang, Jinling Huang, Yinfeng Yang & Jinghui Wang. (2022) The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Frontiers in Oncology 12.
Crossref
Crossref
Damjan Avsec, Marja Škrlj Miklavčič, Tilen Burnik, Maša Kandušer, Maruša Bizjak, Helena Podgornik & Irena Mlinarič-Raščan. (2022) Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax. Cell Death & Disease 13:10.
Crossref
Crossref
Yong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, Raymone Pajarillo, Christopher Tor Sauter, Ruchi Patel, Hatcher J. Ballard, Seok Jae Hong, Inkook Chun, Nicholas Yang, Kimberly V. Amelsberg, Katherine D. Cummins, Jakub Svoboda, Saar Gill, Elise A. Chong, Khrystyna North, Sarah E. Church, Joseph A. Fraietta, Wan-Jung Chang, Simon F. Lacey, Xueqing Maggie Lu, Yunlin Zhang, Kanupriya Whig, David C. Schultz, Sara Cherry, James Gerson, Stephen J. Schuster, Patrizia Porazzi & Marco Ruella. (2022) Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer. Cancer Discovery 12:10, pages 2372-2391.
Crossref
Crossref
Andrei V. Khokhlatchev, Arati Sharma, Tye G. Deering, Jeremy J. P. Shaw, Pedro Costa‐Pinheiro, Upendarrao Golla, Charyguly Annageldiyev, Myles C. Cabot, Mark R. Conaway, Su‐Fern Tan, Johnson Ung, David J. Feith, Thomas P. LoughranJrJr, David F. Claxton, Todd E. Fox & Mark Kester. (2022) Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia. The FASEB Journal 36:10.
Crossref
Crossref
Josep-Maria Ribera & Sabina Chiaretti. (2022) Modern Management Options for Ph+ ALL. Cancers 14:19, pages 4554.
Crossref
Crossref
Michelle Przedborski, David Sharon, Severine Cathelin, Steven Chan & Mohammad Kohandel. (2022) An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia. PLOS Computational Biology 18:9, pages e1010439.
Crossref
Crossref
Anyou Wang, Mingmeng Fang, Hui Jiang, Dongyao Wang, Xuhan Zhang, Baolin Tang, Xiaoyu Zhu, Wanglai Hu & Xin Liu. (2022) Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia. Biomedicine & Pharmacotherapy 153, pages 113527.
Crossref
Crossref
Danai Dima, Dongxu Jiang, Divya Jyoti Singh, Metis Hasipek, Haikoo S. Shah, Fauzia Ullah, Jack Khouri, Jaroslaw P. Maciejewski & Babal K. Jha. (2022) Multiple Myeloma Therapy: Emerging Trends and Challenges. Cancers 14:17, pages 4082.
Crossref
Crossref
Zhenwei Zhang, Linghui Hou, Lijun Bai, Jiying Pei, Shan Zhao, Shenglin Luan, Dan Liu, Min Huang & Linxiang Zhao. (2022) Discovery and structure-activity relationship studies of novel Bcl-2/Mcl-1 dual inhibitors with indole scaffold. Bioorganic Chemistry 125, pages 105845.
Crossref
Crossref
Meghana Manjunath, Sai Swaroop, Sai Sanwid Pradhan, Raksha Rao K, Raghunandan Mahadeva, Venketesh Sivaramakrishnan & Bibha Choudhary. (2022) Integrated Transcriptome and Metabolomic Analysis Reveal Anti-Angiogenic Properties of Disarib, a Novel Bcl2-Specific Inhibitor. Genes 13:7, pages 1208.
Crossref
Crossref
Florian Hagenbourger, Sheila Bohler & Miriam Erlacher. (2022) No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications. Current Opinion in Hematology 29:4, pages 181-187.
Crossref
Crossref
Lucas Becker, Felix Fischer, Julia L. Fleck, Niklas Harland, Alois Herkommer, Arnulf Stenzl, Wilhelm K. Aicher, Katja Schenke-Layland & Julia Marzi. (2022) Data-Driven Identification of Biomarkers for In Situ Monitoring of Drug Treatment in Bladder Cancer Organoids. International Journal of Molecular Sciences 23:13, pages 6956.
Crossref
Crossref
Mika Caplan, Karli J. Wittorf, Kasidy K. Weber, Samantha A. Swenson, Tyler J. Gilbreath, R. Willow Hynes-Smith, Catalina Amador, R. Katherine Hyde & Shannon M. Buckley. (2022) Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML. Leukemia 36:5, pages 1296-1305.
Crossref
Crossref
Eulàlia Genescà & Roberta la Starza. (2022) Early T-Cell Precursor ALL and Beyond: Immature and Ambiguous Lineage T-ALL Subsets. Cancers 14:8, pages 1873.
Crossref
Crossref
Shengrui Feng & Daniel D. De Carvalho. (2021) Clinical advances in targeting epigenetics for cancer therapy. The FEBS Journal 289:5, pages 1214-1239.
Crossref
Crossref
Manfei Pi, Huixian Kuang, Chunyan Yue, Qixuan Yang, Anqin Wu, Yuhua Li, Yehuda G. Assaraf, Dong-Hua Yang & Shaojie Wu. (2022) Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma. Drug Resistance Updates 61, pages 100822.
Crossref
Crossref
Darren Pan & Joshua Richter. (2022) Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. Frontiers in Oncology 11.
Crossref
Crossref
Fieke W. Hoff, Anneke D. Van Dijk, Yihua Qiu, Chenyue W. Hu, Rhonda E. Ries, Andrew Ligeralde, Gaye N. Jenkins, Robert B. Gerbing, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Amina A. Qutub, Eveline S.J.M. De Bont, Terzah M. Horton & Steven M. Kornblau. (2022) Clinical relevance of proteomic profiling in <i>de novo</i> pediatric acute myeloid leukemia: a Children’s Oncology Group study. Haematologica 107:10, pages 2329-2343.
Crossref
Crossref
M.A. Granatkin, Evgenii Aleksandrovich Nikitin, E.S. Mikhailov, V.A. Doronin, S.V. Minenko, M.M. Okuneva, N.V. Degtyareva, M.E. Pochtar, S.A. Lugovskaya, Yu.N. Kobzev, O.Yu. Vinogradova & V.V. Ptushkin. (2022) Azacitidine/Venetoclax Combination as First-Line Therapy in Elderly Patients with Acute Myeloid Leukemias: A First Step. Clinical oncohematology 15:3, pages 282-288.
Crossref
Crossref
Curtis A. Lachowiez, Himachandana Atluri & Courtney D. DiNardo. (2022) Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia. Therapeutic Advances in Hematology 13, pages 204062072210939.
Crossref
Crossref
Bushra Tbakhi & Patrick M. Reagan. (2022) Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). Therapeutic Advances in Hematology 13, pages 204062072210807.
Crossref
Crossref
Meghali Goswami, Gege Gui, Laura W Dillon, Katherine E Lindblad, Julie Thompson, Janet Valdez, Dong-Yun Kim, Jack Y Ghannam, Karolyn A Oetjen, Christin B Destefano, Dana M Smith, Hanna Tekleab, Yeusheng Li, Pradeep Dagur, Thomas Hughes, Jennifer L Marté, Jaydira del Rivero, Joanna Klubo-Gwiezdzinksa, James L Gulley, Katherine R Calvo, Catherine Lai & Christopher S Hourigan. (2022) Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. Journal for ImmunoTherapy of Cancer 10:1, pages e003392.
Crossref
Crossref
Douglas D. Fang, Hengrui Zhu, Qiuqiong Tang, Guangfeng Wang, Ping Min, Qixin Wang, Na Li, Dajun Yang & Yifan Zhai. (2022) FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia. Translational Oncology 15:1, pages 101244.
Crossref
Crossref
Keli Lima, Hugo Passos Vicari, Jorge Antonio Elias Godoy Carlos, Jean Carlos Lipreri da Silva, Lorena Lobo de Figueiredo-Pontes, Eduardo Magalhães Rego & João Agostinho Machado-Neto. (2022) Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy 44:1, pages 124-127.
Crossref
Crossref
Jason Westin, Michael B Maris, Caron A Jacobson, Prapti Patel, Nehal Lakhani, Wael Harb, Dipti Patel-Donnelly, Kelly McCaul, Carolina Escobar, Barbara Klencke & Ayad M. Al-Katib. (2022) Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 22:1, pages 52-59.
Crossref
Crossref
Sergiu Pasca, Helen T. Chifotides, Srdan Verstovsek & Prithviraj Bose. 2022. Cellular and Molecular Aspects of Myeloproliferative Neoplasms – Part B. Cellular and Molecular Aspects of Myeloproliferative Neoplasms – Part B
83
124
.
Nicole Bata & Nicholas D. P. Cosford. (2021) Cell Survival and Cell Death at the Intersection of Autophagy and Apoptosis: Implications for Current and Future Cancer Therapeutics. ACS Pharmacology & Translational Science 4:6, pages 1728-1746.
Crossref
Crossref
Bin-Ru Wang, Chao-Ling Wan, Song-Bai Liu, Qiao-Cheng Qiu, Tian-Mei Wu, Jun Wang, Yan-Yan Li, Shuai-Shuai Ge, Yan Qiu, Xiang-Dong Shen, Sheng-Li Xue & Zheng Li. (2021) A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports. Frontiers in Oncology 11.
Crossref
Crossref
Laura Ballotta, Pier Luigi Zinzani, Stefano Pileri, Riccardo Bruna, Monica Tani, Beatrice Casadei, Valentina Tabanelli, Stefano Volpetti, Stefano Luminari, Paolo Corradini, Elisa Lucchini, Maria Chiara Tisi, Michele Merli, Alessandro Re, Marzia Varettoni, Emanuela Anna Pesce & Francesco Zaja. (2021) Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi. Frontiers in Oncology 11.
Crossref
Crossref
A. D. van Dijk, F. W. Hoff, Y. H. Qiu, J. Chandra, E. Jabbour, E. S. J. M. de Bont, T. M. Horton & S. M. Kornblau. (2021) Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia. Clinical Epigenetics 13:1.
Crossref
Crossref
Wael Harb, Nehal J. Lakhani, Richard Messmann, Barbara Klencke & Ayad M. Al-Katib. (2021) A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma and Leukemia 21:12, pages 823-830.
Crossref
Crossref
Yuliya Yakymiv, Stefania Augeri, Cristiano Bracci, Sara Marchisio, Semra Aydin, Stefano D’Ardia, Massimo Massaia, Enza Ferrero, Erika Ortolan & Ada Funaro. (2021) CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1. Scientific Reports 11:1.
Crossref
Crossref
Ayano Nakamura, Susumu Suzuki, Jo Kanasugi, Masayuki Ejiri, Ichiro Hanamura, Ryuzo Ueda, Masao Seto & Akiyoshi Takami. (2021) Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma. International Journal of Molecular Sciences 22:19, pages 10761.
Crossref
Crossref
Khashayar Ahmadmehrabi, Ali R. Haque, Ahmed Aleem, Elizabeth A. Griffiths & Gregory W. Roloff. (2021) Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia. Cancers 13:18, pages 4646.
Crossref
Crossref
Lars Kurch, Andreas Hüttmann, Thomas W. Georgi, Jan Rekowski, Osama Sabri, Christine Schmitz, Regine Kluge, Ulrich Dührsen & Dirk Hasenclever. (2021) Interim PET in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine 62:8, pages 1068-1074.
Crossref
Crossref
Gabriel Prado, Charlotte L. Kaestner, Jonathan D. Licht & Richard L. Bennett. (2021) Targeting epigenetic mechanisms to overcome venetoclax resistance. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1868:8, pages 119047.
Crossref
Crossref
Nicholas J. Short, Marina Konopleva, Tapan Kadia, Partow Kebriaei, Naval Daver, Xuelin Huang, Lucia Masarova, Robin Cook, Nitin Jain, Elias Jabbour, Hagop Kantarjian & Farhad Ravandi. (2021)
An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory
P
hiladelphia chromosome‐positive acute lymphoblastic leukemia
. American Journal of Hematology 96:7.
Crossref
Crossref
Haneen T. Salah, Courtney D. DiNardo, Marina Konopleva & Joseph D. Khoury. (2021) Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions. Cancers 13:12, pages 2974.
Crossref
Crossref
Justin P. Pogmore, David Uehling & David W. Andrews. (2021) Pharmacological Targeting of Executioner Proteins: Controlling Life and Death. Journal of Medicinal Chemistry 64:9, pages 5276-5290.
Crossref
Crossref
Carter K. FairchildJr.Jr., Konstantinos V. Floros, Sheeba Jacob, Colin M. Coon, Madhavi Puchalapalli, Bin Hu, Hisashi Harada, Mikhail G. Dozmorov, Jennifer E. Koblinski, Steven C. Smith, Gregory Domson, Joel D. Leverson, Andrew J. Souers, Naoko Takebe, Hiromichi Ebi, Anthony C. Faber & Sosipatros A. Boikos. (2021) Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA. Cancers 13:10, pages 2310.
Crossref
Crossref
Milagros Suarez, Gavin T. Blyth, Alain A. Mina, Ewa M. Kosciuczuk, Blazej Dolniak, Shira Dinner, Jessica K. Altman, Elizabeth A. Eklund, Diana Saleiro, Elspeth M. Beauchamp & Leonidas C. Platanias. (2021) Inhibitory effects of Tomivosertib in acute myeloid leukemia. Oncotarget 12:10, pages 955-966.
Crossref
Crossref
Lucia Masarova, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval G. Daver, Tapan M. Kadia, Helen T. Chifotides, Lingsha Zhou, Gautam Borthakur, Zeev Estrov, Marina Konopleva & Srdan Verstovsek. (2021) Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Advances 5:8, pages 2156-2164.
Crossref
Crossref
Marta Weronika Lato, Anna Przysucha, Sylwia Grosman, Joanna Zawitkowska & Monika Lejman. (2021) The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences 22:9, pages 4502.
Crossref
Crossref
Lee-or Herzog, Beth Walters, Roberta Buono, J. Scott Lee, Sharmila Mallya, Amos Fung, Honyin Chiu, Nancy Nguyen, Boyang Li, Anthony B. Pinkerton, Michael R. Jackson, Robert J. Schneider, Ze’ev A. Ronai & David A. Fruman. (2020) Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. British Journal of Cancer 124:6, pages 1098-1109.
Crossref
Crossref
Delin Yuan, Genhong Li, Lian Yu, Yuelong Jiang, Yuanfei Shi, Qiulin Chen, Xiaomei Ma, Lan V. Pham, Ken H. Young, Manman Deng, Zhihong Fang & Bing Xu. (2021) CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements. Frontiers in Oncology 11.
Crossref
Crossref
Hailong Tang, Shuangshuang Jia, Lei Bi, Weijing Jia & Guangxun Gao. (2021) Treatment options for older unfit patients with acute myeloid leukemia. Future Oncology 17:7, pages 837-851.
Crossref
Crossref
Marina Y. Konopleva. (2021) Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax. Best Practice & Research Clinical Haematology 34:1, pages 101251.
Crossref
Crossref
Martin Grundy, Firas Al‐Kaisi, Joanna Cull, Cathy Williams, Dean Smith & Claire H. Seedhouse. (2020) A same‐day assay predicts apoptotic response to combined BCL‐2 and MCL‐1 BH3‐mimetic targeting in multiple myeloma cells. eJHaem 2:1, pages 40-47.
Crossref
Crossref
Jan Rekowski, Andreas Hüttmann, Christine Schmitz, Stefan P. Müller, Lars Kurch, Jörg Kotzerke, Christiane Franzius, Matthias Weckesser, Frank M. Bengel, Martin Freesmeyer, Andreas Hertel, Thomas Krohn, Jens Holzinger, Ingo Brink, Uwe Haberkorn, Fonyuy Nyuyki, Daniëlle M.E. van Assema, Lilli Geworski, Dirk Hasenclever, Karl-Heinz Jöckel & Ulrich Dührsen. (2021)
Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUV
max
Method
. Journal of Nuclear Medicine 62:1, pages 37-42.
Crossref
Crossref
Zemene Demelash Kifle, Meklit Tadele, Eyerusalem Alemu, Tadele Gedamu & Akeberegn Gorems Ayele. (2021) A recent development of new therapeutic agents and novel drug targets for cancer treatment. SAGE Open Medicine 9, pages 205031212110670.
Crossref
Crossref
Torsten Schöneberg & Ines Liebscher. (2020) Mutations in G Protein–Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approaches. Pharmacological Reviews 73:1, pages 89-119.
Crossref
Crossref
Kexue Li. (2021) Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology. Bioorganic & Medicinal Chemistry Letters 32, pages 127717.
Crossref
Crossref
Bing Z. Carter, Po Yee Mak, Wenjing Tao, Marc Warmoes, Philip L. Lorenzi, Duncan Mak, Vivian Ruvolo, Lin Tan, Justin Cidado, Lisa Drew & Michael Andreeff. (2020) Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica 107:1, pages 58-76.
Crossref
Crossref
Jaco A. C. van Bruggen, Anne W. J. Martens, Sanne H. Tonino & Arnon P. Kater. (2020) Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 12:12, pages 3837.
Crossref
Crossref
Jenna L. Carter, Katie Hege, Jay Yang, Hasini A. Kalpage, Yongwei Su, Holly Edwards, Maik Hüttemann, Jeffrey W. Taub & Yubin Ge. (2020) Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Srividya B. Balachander, Steven W. Criscione, Kate F. Byth, Justin Cidado, Ammar Adam, Paula Lewis, Terry Macintyre, Shenghua Wen, Deborah Lawson, Kathleen Burke, Tristan Lubinski, Jeffrey W. Tyner, Stephen E. Kurtz, Shannon K. McWeeney, Jeffrey Varnes, R. Bruce Diebold, Thomas Gero, Stephanos Ioannidis, Edward J. Hennessy, William McCoull, Jamal C. Saeh, Areya Tabatabai, Omid Tavana, Nancy Su, Alwin Schuller, Mathew J. Garnett, Patricia Jaaks, Elizabeth A. Coker, Gareth P. Gregory, Andrea Newbold, Ricky W. Johnstone, Eric Gangl, Martin Wild, Michael Zinda, J. Paul Secrist, Barry R. Davies, Stephen E. Fawell & Francis D. Gibbons. (2020) AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. Clinical Cancer Research 26:24, pages 6535-6549.
Crossref
Crossref
Yonghan He, Raphael Koch, Vivekananda Budamagunta, Peiyi Zhang, Xuan Zhang, Sajid Khan, Dinesh Thummuri, Yuma T. Ortiz, Xin Zhang, Dongwen Lv, Janet S. Wiegand, Wen Li, Adam C. Palmer, Guangrong Zheng, David M. Weinstock & Daohong Zhou. (2020) DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
XiaoYan Yue, Qingxiao Chen & JingSong He. (2020) Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer Cell International 20:1.
Crossref
Crossref
Avraham Frisch, Jacob M. Rowe & Yishai Ofran. (2020) How we treat older patients with acute myeloid leukaemia. British Journal of Haematology 191:5, pages 682-691.
Crossref
Crossref
Madeleine R. Berendsen, Wendy B. C. Stevens, Michiel van den Brand, J. Han van Krieken & Blanca Scheijen. (2020) Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance. Cancers 12:12, pages 3553.
Crossref
Crossref
Yunxiong Wei, Yaqing Cao, Rui Sun, Lin Cheng, Xia Xiong, Xin Jin, Xiaoyuan He, Wenyi Lu & Mingfeng Zhao. (2020) Targeting Bcl-2 Proteins in Acute Myeloid Leukemia. Frontiers in Oncology 10.
Crossref
Crossref
Andrew H. Wei, Andrew W. Roberts, Andrew Spencer, Aaron Seth Rosenberg, David Siegel, Roland B. Walter, Sean Caenepeel, Paul Hughes, Zach McIver, Khalid Mezzi, Phuong Khanh Morrow & Anthony Stein. (2020) Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Reviews 44, pages 100672.
Crossref
Crossref
Marije B. Overdijk, Kristin Strumane, Frank J. Beurskens, Antonio Ortiz Buijsse, Claudine Vermot-Desroches, Boris S. Vuillermoz, Thessa Kroes, Bart de Jong, Naomi Hoevenaars, Richard G. Hibbert, Andreas Lingnau, Ulf Forssmann, Janine Schuurman, Paul W.H.I. Parren, Rob N. de Jong & Esther C.W. Breij. (2020) Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Molecular Cancer Therapeutics 19:10, pages 2126-2138.
Crossref
Crossref
Salihanur Darici, Hazem Alkhaldi, Gillian Horne, Heather G. Jørgensen, Sandra Marmiroli & Xu Huang. (2020) Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. Journal of Clinical Medicine 9:9, pages 2934.
Crossref
Crossref
Xiangmeng Wang, Po Yee Mak, Hong Mu, Wenjing Tao, Arvind Rao, Ravikumar Visweswaran, Vivian Ruvolo, Jonathan A. Pachter, David T. Weaver, Michael Andreeff, Bing Xu & Bing Z. Carter. (2020) Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. Molecular Cancer Therapeutics 19:8, pages 1636-1648.
Crossref
Crossref
Francis R. LeBlanc, Jennifer M. Pearson, Su‐Fern Tan, HeeJin Cheon, Jeffrey C. Xing, Wendy Dunton, David J. Feith & Thomas P. LoughranJrJr. (2020) Sphingosine kinase‐2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl‐1. British Journal of Haematology 190:3, pages 405-417.
Crossref
Crossref
Tamás Györke, Robert Carr, Juliano J. Cerci, Claudio Meneghetti, Francisca Redondo, Monica Celli, Charity Gorospe, Chirayu U. Auewarakul, Linda Jorgov, Diana Paez & Stefano Fanti. (2020)
Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment
18
F-FDG PET in Diffuse Large B-Cell Lymphoma
. Journal of Nuclear Medicine 61:7, pages 999-1005.
Crossref
Crossref
Benedito A. Carneiro & Wafik S. El-Deiry. (2020) Targeting apoptosis in cancer therapy. Nature Reviews Clinical Oncology 17:7, pages 395-417.
Crossref
Crossref
Samantha J. Jones, Sumara Stroshein, Amy M. Williams, Dongmeng Liu, John J. Spinelli, Joseph M. Connors & Angela R. Brooks-Wilson. (2020) Birth Order, Sibship Size, Childhood Environment and Immune-Related Disorders, and Risk of Lymphoma in Lymphoid Cancer Families. Cancer Epidemiology, Biomarkers & Prevention 29:6, pages 1168-1178.
Crossref
Crossref
Cristina Panuzzo, Aleksandar Jovanovski, Barbara Pergolizzi, Lucrezia Pironi, Serena Stanga, Carmen Fava & Daniela Cilloni. (2020) Mitochondria: A Galaxy in the Hematopoietic and Leukemic Stem Cell Universe. International Journal of Molecular Sciences 21:11, pages 3928.
Crossref
Crossref
Simona D’Aguanno & Donatella Del Bufalo. (2020) Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells 9:5, pages 1287.
Crossref
Crossref
Raghuveer Singh Mali, Qi Zhang, RosaAnna DeFilippis, Antonio Cavazos, Vinitha Mary Kuruvilla, Jayant Raman, Vidhi Mody, Edna F. Choo, Monique Dail, Neil P. Shah, Marina Konopleva, Deepak Sampath & Elisabeth A. Lasater. (2020) Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica 106:4, pages 1034-1046.
Crossref
Crossref
Nicholas J. Short, Marina Konopleva, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Courtney D. DiNardo & Naval Daver. (2020) Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discovery 10:4, pages 506-525.
Crossref
Crossref
Lulu Liu, Renshuai Liu, Xinying Yang, Xuben Hou & Hao Fang. (2020) Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors. European Journal of Medicinal Chemistry 191, pages 112142.
Crossref
Crossref
Till Braun, Jana von Jan, Linus Wahnschaffe & Marco Herling. (2020) Advances and Perspectives in the Treatment of T-PLL. Current Hematologic Malignancy Reports 15:2, pages 113-124.
Crossref
Crossref
Darren PanRaajit Rampal & John Mascarenhas. (2020) Clinical developments in epigenetic-directed therapies in acute myeloid leukemia. Blood Advances 4:5, pages 970-982.
Crossref
Crossref
Seth E. Karol & Ching-Hon Pui. (2020) Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia. Therapeutic Advances in Hematology 11, pages 204062072092757.
Crossref
Crossref
Giovanna Carrà, Paolo Nicoli, Marcello Francesco Lingua, Beatrice Maffeo, Antonio Cartellà, Paola Circosta, Mara Brancaccio, Guido Parvis, Valentina Gaidano, Angelo Guerrasio, Giuseppe Saglio, Riccardo Taulli & Alessandro Morotti. (2019) Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia. Journal of Cellular and Molecular Medicine 24:2, pages 1650-1657.
Crossref
Crossref
Hongxia Wang, Junjun Bai, Zhixin Pei, Bei Zhang, Junjie Wang, Xingli Lian & Qinglin Song. (2020) Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia. Medicine 99:47, pages e23265.
Crossref
Crossref
Jinming Song, Rohit Sharma & Mohammad Hussaini. 2020. Diagnostic Pathology of Hematopoietic Disorders of Spleen and Liver. Diagnostic Pathology of Hematopoietic Disorders of Spleen and Liver
37
67
.
Roberta La Starza, Benedetta Cambò, Antonio Pierini, Beat Bornhauser, Anna Montanaro, Jean-Pierre Bourquin, Cristina Mecucci & Giovanni Roti. (2019) Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia. JCO Precision Oncology:3, pages 1-6.
Crossref
Crossref
Jonathan R. Sillar & Anoop K. Enjeti. (2019) Targeting Apoptotic Pathways in Acute Myeloid Leukaemia. Cancers 11:11, pages 1660.
Crossref
Crossref
Francesca Pentimalli, Sandro Grelli, Nicola Di Daniele, Gerry Melino & Ivano Amelio. (2018) Cell death pathologies: targeting death pathways and the immune system for cancer therapy. Genes & Immunity 20:7, pages 539-554.
Crossref
Crossref
Filippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, Chiara Tarantelli, Luciano Cascione, Sara Napoli, Katti Jessen, Laura Carrassa, Valdemar Priebe, Giulio Sartori, Garrett Graham, Saravana P. Selvanathan, Andrea Cavalli, Andrea Rinaldi, Ivo Kwee, Monica Testoni, Davide Genini, B. Hilda Ye, Emanuele Zucca, Anastasios Stathis, Brian Lannutti, Jeffrey A. Toretsky & Francesco Bertoni. (2019) The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. Clinical Cancer Research 25:16, pages 5167-5176.
Crossref
Crossref
Megan M. HerrSara J. SchonfeldGraça M. Dores, Eric A. Engels, Margaret A. Tucker, Rochelle E. CurtisLindsay M. Morton. (2019) Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes. Blood Advances 3:13, pages 1961-1969.
Crossref
Crossref
Xufeng Chen, Christina Glytsou, Hua Zhou, Sonali Narang, Denis E. Reyna, Andrea Lopez, Theodore Sakellaropoulos, Yixiao Gong, Andreas Kloetgen, Yoon Sing Yap, Eric Wang, Evripidis Gavathiotis, Aristotelis Tsirigos, Raoul Tibes & Iannis Aifantis. (2019) Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Cancer Discovery 9:7, pages 890-909.
Crossref
Crossref
Brittany Knick Ragon, Olatoyosi Odenike, Maria R. Baer, Wendy Stock, Gautam Borthakur, Keyur Patel, Lina Han, Helen Chen, Helen Ma, Loren Joseph, Yang Zhao, Keith Baggerly, Marina Konopleva & Nitin Jain. (2019) Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clinical Lymphoma Myeloma and Leukemia 19:7, pages 431-440.e13.
Crossref
Crossref
Jian‐min Sun, Hai‐tao Xu, Liang Zhao, Yu‐bao Zhang, Peng‐cheng Kang, Zeng‐fu Song, Hai‐shi Liu & Yun‐Fu Cui. (2019) Induction of cell‐cycle arrest and apoptosis in human cholangiocarcinoma cells by pristimerin. Journal of Cellular Biochemistry 120:7, pages 12002-12009.
Crossref
Crossref
Elena Follini, Matteo Marchesini & Giovanni Roti. (2019) Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences 20:12, pages 3021.
Crossref
Crossref
Alexander W. Hird & Adriana E. Tron. (2019) Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacology & Therapeutics 198, pages 59-67.
Crossref
Crossref
Daniel A.R. Heisey, Timothy L. Lochmann, Konstantinos V. Floros, Colin M. Coon, Krista M. Powell, Sheeba Jacob, Marissa L. Calbert, Maninderjit S. Ghotra, Giovanna T. Stein, Yuki Kato Maves, Steven C. Smith, Cyril H. Benes, Joel D. Leverson, Andrew J. Souers, Sosipatros A. Boikos & Anthony C. Faber. (2019) The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity. Clinical Cancer Research 25:5, pages 1664-1675.
Crossref
Crossref
Meletios DimopoulosDavid SiegelDarrell J. WhiteRalph BocciaKarim S. IskanderZhao YangAmy S. KimballKhalid MezziHeinz Ludwig & Ruben Niesvizky. (2019) Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood 133:2, pages 147-155.
Crossref
Crossref
Courtney D. DiNardoKeith PratzVinod PullarkatBrian A. JonasMartha ArellanoPamela S. BeckerOlga FrankfurtMarina KonoplevaAndrew H. WeiHagop M. KantarjianTu XuWan-Jen HongBrenda ChylaJalaja PotluriDaniel A. Pollyea & Anthony Letai. (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:1, pages 7-17.
Crossref
Crossref
James D’Rozario & Samuel K. Bennett. (2019) Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL. Therapeutic Advances in Hematology 10, pages 204062071984469.
Crossref
Crossref
Martin Grundy, Sahana Balakrishnan, Matthew Fox, Claire H. Seedhouse & Nigel H. Russell. (2018) Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells. Oncotarget 9:102, pages 37777-37789.
Crossref
Crossref
Gerardo Ferrer & Emili Montserrat. (2018) Critical molecular pathways in CLL therapy. Molecular Medicine 24:1.
Crossref
Crossref
Daniel A. Pollyea. (2018) New drugs for acute myeloid leukemia inspired by genomics and when to use them. Hematology 2018:1, pages 45-50.
Crossref
Crossref
Anne Slomp & Victor Peperzak. (2018) Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma. Frontiers in Oncology 8.
Crossref
Crossref
Maurilio Ponzoni, Elias Campo & Shigeo Nakamura. (2018) Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood 132:15, pages 1561-1567.
Crossref
Crossref
Bingshan Liu, Roshni Narurkar, Madhura Hanmantgad, Wahib Zafar, Yongping Song & Delong Liu. (2018) Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report. Frontiers of Medicine 12:5, pages 593-599.
Crossref
Crossref
S. de Vos, L.J. Swinnen, D. Wang, E. Reid, N. Fowler, J. Cordero, M. Dunbar, S.H. Enschede, C. Nolan, A.M. Petrich, J.A. Ross, A.H. Salem, M. Verdugo, S. Agarwal, L. Zhou, M. Kozloff, L.J. Nastoupil & C.R. Flowers. (2018) Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Annals of Oncology 29:9, pages 1932-1938.
Crossref
Crossref
Prashant Sharma & Daniel A Pollyea. (2018) Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition. Current Hematologic Malignancy Reports 13:4, pages 256-264.
Crossref
Crossref
Silvia MaifredeMargaret Nieborowska-SkorskaKatherine Sullivan-ReedYashodhara DasguptaPaulina Podszywalow-BartnickaBac Viet LeMartyna SoleckaZhaorui LianElizaveta A. BelyaevaAlina NersesyanMarcin M. MachnickiMonika TomaNicolas ChatainMalgorzata RydzaniczHuaqing Zhao, Jaroslav JelinekKatarzyna PiwockaTomasz SliwinskiTomasz StoklosaRafal PloskiThomas FischerStephen M. SykesSteffen KoschmiederLars Bullinger, Peter Valent, Mariusz A. WasikJian HuangTomasz Skorski. (2018) Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood 132:1, pages 67-77.
Crossref
Crossref
A. Esteve-Arenys, J. G. Valero, A. Chamorro-Jorganes, D. Gonzalez, V. Rodriguez, I. Dlouhy, I. Salaverria, E. Campo, D. Colomer, A. Martinez, G. Rymkiewicz, P. Pérez-Galán, A. Lopez-Guillermo & G. Roué. (2018) The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene 37:14, pages 1830-1844.
Crossref
Crossref
Ravi Bhatia. (2017) Novel approaches to therapy in CML. Hematology 2017:1, pages 115-120.
Crossref
Crossref
Prithviraj Bose & Marina Y. Konopleva. (2017) T-PLL: another check on the venetoclax list?. Blood 130:23, pages 2447-2448.
Crossref
Crossref
Astrid Ruefli-Brasse & John C. Reed. (2017) Therapeutics targeting Bcl-2 in hematological malignancies. Biochemical Journal 474:21, pages 3643-3657.
Crossref
Crossref
Lawrence M Agius. (2017) Contextual Pre-Conditioning and Sustained Conditioning of Cells Dictate Cell-Target Therapeutic Outcome in Tumor Cell Apoptosis/Anti-Apoptosis. International Journal of Radiology & Radiation Therapy 2:3.
Crossref
Crossref
Prithviraj Bose & Varsha Gandhi. (2017) Recent therapeutic advances in chronic lymphocytic leukemia. F1000Research 6, pages 1924.
Crossref
Crossref